Search

Displaying results 3621 - 3630 of 10000 in total
  1. Pathway

    De Novo Triacylglycerol Biosynthesis TG(22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)/22:5(7Z,10Z,13Z,16Z,19Z))

    smpdb.ca/view/SMP0025386
    Metabolic

    A triglyceride (TG, triacylglycerol, TAG, or triacylglyceride) is an ester derived from glycerol and three fatty acids. Triglycerides are the main constituents of body fat in humans and other animals, as well as vegetable fat. They are a...

    Drugs: NADH · sn-glycerol 3-phosphate · Dihydroxyacetone phosphate
  2. Drug

    LLL-3348

    go.drugbank.com/drugs/DB05771
    Experimental

    The botanical drug product LLL-3348 is a once-daily oral formulation for treatment of chronic stable plaque type psoriasis.

  3. Drug

    Agerafenib

    go.drugbank.com/drugs/DB15068
    Investigational

    Agerafenib is under investigation in clinical trial NCT03052569 (Expanded Access to RXDX-105 for Cancers With RET Alterations).

  4. Drug

    Tiletamine

    go.drugbank.com/drugs/DB11549
    ExperimentalVet approved

    Tiletamine hydrochloride, the salt form, exists as odorless white crystals.

    Mixtures: Zoletil 100 Injectable Anaesthetic, Zoletil 50 Injectable Anaesthetic
  5. Pathway

    Phosphatidylethanolamine Biosynthesis PE(22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))

    smpdb.ca/view/SMP0015745
    Metabolic

    Phosphatidylserine, itself, is synthesized using a base-exchange reaction with phosphatidylcholine.

    Drugs: Choline · Serine · Phosphatidyl serine · ATP · Cytidine-5'-Triphosphate · Ethanolamine +1 more
  6. Drug

    Inulin

    go.drugbank.com/drugs/DB00638
    ApprovedInvestigationalNutraceutical

    Since it is hydrolyzable to fructose, it is classified as a fructosan. It has been used in physiologic investigation for determination of the rate of glomerular function.

  7. Drug

    Diphenidol

    go.drugbank.com/drugs/DB01231
    ApprovedWithdrawn

    Diphenidol is an antiemetic agent used in the treatment of vomiting and vertigo. Diphenidol overdose may result in serious toxicity in children.

  8. Drug

    Infigratinib

    go.drugbank.com/drugs/DB11886
    ApprovedInvestigationalWithdrawn

    [A198963] Infitratinib is a pan-FGFR inhibitor, as it is an ATP-competitive inhibitor of all four FGFR receptor subtypes. … By inhibiting the FGFR pathway, which is often aberrated in cancers such as cholangiocarcinoma, infigratinib suppresses tumour growth.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  9. Drug

    Pirtobrutinib

    go.drugbank.com/drugs/DB17472
    ApprovedInvestigational

    [A256758,A256773,L44863] However, other mutations may confer resistance to non-covalent BTK inhibitors such as pirtobrutinib. … Its high selectivity has been associated with lower discontinuation rates due to adverse events and a lower incidence of atrial fibrillation.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InducersSynonyms: (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide, 5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-((2s)-1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
  10. Pathway

    Disperse Blue 106 Drug Metabolism

    smpdb.ca/view/SMP0130759
    Metabolic

    Disperse Blue 106 passes through the liver and is then excreted from the body mainly through the kidney. … Disperse Blue 106 is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis.

    Drugs: Disperse Blue 106